Shinor Biosciences

Shinor Biosciences is a clinical-stage biotechnology company focused on developing next-generation small molecule therapies for metabolic and liver diseases. The company's lead research program centers on highly selective thyroid hormone receptor beta (THR-beta) agonists designed to treat metabolic dysfunction-associated steatohepatitis (MASH) and related metabolic disorders. By targeting THR-beta specifically, Shinor aims to improve lipid metabolism and reduce liver fat while avoiding the cardiac and bone-related side effects typically associated with THR-alpha activation. The company's pipeline includes SNB-101, which is being advanced for MASH and obesity indications. Shinor Biosciences is headquartered in Rockville, Maryland, and led by a team with extensive experience in drug discovery and development.